About
About KAINOS Laboratories, Inc
KAINOS Laboratories, Inc. develops, manufactures, markets, distributes, and imports/exports pharmaceuticals, diagnostic reagents, related chemical products, physical and chemical measurement instruments, medical supplies, nutrition supplements, foodstuff, animal feed, and related products in Japan. The company offers various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-III plus Test Kit for automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. It also provides FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum; Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for use in detecting type a and type b influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan.
Visit company website
5 years, 5 months ago
KAINOS Laboratories, Inc is currently in a long term uptrend where the price is trading 27.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
KAINOS Laboratories, Inc's total revenue sank by 11.9% to $1B since the same quarter in the previous year.
Its net income has dropped by 14.2% to $140M since the same quarter in the previous year.
Based on the above factors, KAINOS Laboratories, Inc gets an overall score of 2/5.